Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert Burger, MD
Mersana Therapeutics
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Epworth Richmond
Richmond, Victoria, Australia
- Sherbrooke University Hospital Centre
Québec, Sherbrooke, Canada
- Honorhealth Research Institute - Honorhealth Vgpcc Biltmore
Phoenix, Arizona, United States
- the University of Arizona Cancer Center
Tucson, Arizona, United States
- University of California Los Angeles, Gynecologic Oncology Clinic
Los Angeles, California, United States
- University of California, Irvine Medical Center
Orange, California, United States
- Sarasota Memorial Hospital
Sarasota, Florida, United States
- University of Chicago Medical Center
Chicago, Illinois, United States
- Wk Physicians
Shreveport, Louisiana, United States
- Karmanos Cancer Institute - Detroit
Detroit, Michigan, United States
- Billings Clinic
Billings, Montana, United States
- Methodist Hospital
Omaha, Nebraska, United States
- Women'S Cancer Center of Nevada
Las Vegas, Nevada, United States
- Center of Hope
Reno, Nevada, United States
- Southwest Women'S Oncology
Albuquerque, New Mexico, United States
- University of New Mexico Cancer Center
Albuquerque, New Mexico, United States
- University Hospitals Cleveland Medical Center, Seidman Cancer Center
Cleveland, Ohio, United States
- Kettering Health Cancer Center
Kettering, Ohio, United States
- Stephenson Cancer Center
Oklahoma City, Oklahoma, United States
- Willamette Valley Cancer Institute and Research Center
Eugene, Oregon, United States
- Legacy Good Samaritan Medical Center - Legacy Medical Group - Gynecologic Oncology
Portland, Oregon, United States
- Asplundh Cancer Pavilion
Willow Grove, Pennsylvania, United States
- Avera Mckennan D/b/a Avera Research Institute
Sioux Falls, South Dakota, United States
- Sanford Gynecologic Oncology
Sioux Falls, South Dakota, United States
- Texas Oncology P.A. - Austin
Austin, Texas, United States
- Texas Oncology - Dfww
Bedford, Texas, United States
- Texas Oncology - Tyler
Tyler, Texas, United States
- Vcu Massey Cancer Center
Richmond, Virginia, United States
- University of Wisconsin Clinical Science Center
Madison, Wisconsin, United States
- Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 23 Jun 2022
- Primary completion
- 29 Sept 2023
- Completion
- 29 Sept 2023
- Last update posted
- 26 Oct 2023
- Registered enrollment
- 20
- Registry id
- NCT05329545
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.